U.S. Construction Stock News

Amerant Bancorp (AMTB) has just priced and closed a $50 million issue of 7.00% senior notes due 2031, a move that reshapes its funding mix and near term financial flexibility. Amerant Bancorp’s new 7.00% notes come on the back of strong momentum, with a 90 day share price return of 22.73% and a year to date share price gain of 51.19% at a latest share price of $29.80. The 3 year total shareholder return of 73.70% suggests longer term holders have already seen meaningful compounding as the...

With the Fed funds rate now at 3.75–4.00% and Treasury bills offering eye catching yields, short term cash is no longer a boring corner of the market. Investors who once left idle balances untouched are rethinking where every dollar sits, and which platforms benefit when that cash flows into money-market and sweep accounts. This article walks through three stocks from our U.S. short duration cash and money-market platform screener that appear especially exposed to this rate driven story. The...

BlackRock recently launched LifePath Solutions, a customizable target date framework built on its US$770b LifePath platform. It offers tailored plan and participant analysis, private and public market exposure, and optional guaranteed lifetime income within workplace retirement plans. The framework effectively brings tools often used in traditional pensions into defined contribution plans of varying sizes, including lifetime income features and demographic-based glidepath design. This...

Carter's recently launched its Not-So-Scary Monsters sleepwear and playwear line, featuring character-led bedtime helpers and app-based Monster Room Scanner tools, with prices ranging from $7 to $28 across baby through big-kid sizes. The collection blends Carter's core sleepwear franchise with a digital feature in the Carter's app, signaling an effort to deepen engagement with existing families and potentially support demand in a structurally pressured childrenswear market. This article will...

Biogen and Eisai recently reported multiple product updates, including Japan and China approvals for at-home subcutaneous LEQEMBI and fresh adolescent EMPAVELI Phase 3 data showing clinically meaningful proteinuria reductions and kidney function stabilization in rare kidney disease. These moves concentrate Biogen’s efforts on therapies that can be administered at home or in younger high-need patients. This can reshape treatment logistics, operational demands, and long-term demand visibility...

One thing we could say about the analysts on MindWalk Holdings Corp. ( NASDAQ:HYFT ) - they aren't optimistic, having...

Fed governor Austan Goolsbee is hinting at more rate hikes and more pain for workers, which pushes a lot of fast growth stories to the sidelines and suddenly makes reliable cash payouts look far more interesting. Investors hunting for steadier dividends and tempered volatility may not want to wait until a full recession headline hits. This article walks through three defensive dividend stocks that are exposed to these Fed risks and explains why they deserve a closer look now. The three stocks...

Carpenter Technology (NYSE:CRS) has been added to the FTSE All-World Index, expanding its presence in a key global benchmark. The index inclusion brings Carpenter Technology onto the radar of index-tracking funds and benchmark-aware institutional investors worldwide. The FTSE All-World Index addition creates a new reference point for how global portfolio managers classify Carpenter Technology within diversified portfolios. The fresh FTSE All-World Index inclusion sits against a broader set...

Columbia Financial, Inc. was added to the S&P Banks Select Industry Index in September 2026, marking its inclusion in a widely followed sector benchmark. This index addition places Columbia Financial alongside a broader peer group, which can influence how investors compare its business scale, profitability profile, and balance sheet resilience. We will now look at how Columbia Financial's investment narrative may shift as index inclusion reshapes attention on its core banking...

Kodiak Sciences (KOD) drew fresh attention after recent trading left the share price at US$32.71, with returns over the past month and past 3 months both showing declines. Recent trading pressure has taken some heat out of Kodiak Sciences, with the share price return down 14.66% over the past 30 days and 11.71% over 3 months, even though the year-to-date share price return is 25.71% and the 1-year total shareholder return is 117.92%. This points to fading short-term momentum after a very...

Baird’s September 14 downgrade of several sportswear stocks put Under Armour (UAA) back under the microscope as investors reconsider expectations for athletic apparel demand and consumer spending resilience. Under Armour’s latest share price of US$4.88 comes after a 1-day share price return of down 1.81% and a 30-day share price return of down 9.46%. This extends a 90-day share price return of down 15.57%, even as the 1-year total shareholder return is slightly positive at 2.09%. This signals...

Tech stocks are stealing headlines after Intel’s surge and the Nasdaq 100’s three month high, but the sharp 5.1% slide in crude oil could matter just as much for passenger airlines, whose fuel bills often shape profits. Falling energy prices, upbeat equity sentiment and ongoing Fed uncertainty are creating winners and laggards. This article explains how that mix affects aviation and highlights three stocks exposed to the news. The three aviation and transport stocks below are just a starting...

Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY003 in ulcerative colitis, with the drug meeting all key objectives and showing a safety profile in line with other IL-23 therapies. The update confirms clinical proof-of-concept across all three inflammatory bowel disease mechanisms in Spyre Therapeutics' portfolio. This supports its plan to test higher dose monotherapy and combination regimens in the actively enrolling Part B of...

A blockbuster merger between Paramount and Warner Bros Discovery, now cleared of a major antitrust hurdle, is reshaping how streaming and ad-supported video platforms think about scale, content output and regulatory scrutiny. That shift can create both openings and blind spots for investors who ignore it. This article unpacks the news and then walks through 3 stocks exposed to these changes, highlighting where the risks and potential rewards now look most interesting. The three stocks covered...

Eli Lilly received full U.S. FDA approval for Inluriyo, an oral estrogen receptor antagonist, in combination with Verzenio for adults with ER+, HER2–, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy, based on Phase 3 EMBER-3 data. The new all-oral regimen targets two key drivers of ER+ breast cancer while maintaining an established tolerability profile, which reinforces Eli Lilly's focus on broadening oncology...

Keysight Technologies recently highlighted strong wireline demand tied to AI data centers, expanded manufacturing and supply-chain capacity, and showcased high-speed optical and AI test solutions spanning photonic design, 1.6T optical validation, and AI-enabled test automation. Management also flagged potential acquisitions of smaller suppliers to internalize critical capabilities, pointing to a tighter grip on its supply chain and cost structure while keeping a disciplined return-above-WACC...

When the Federal Reserve lifts rates toward 4% and the 10 year Treasury sits near 5%, cash suddenly feels less boring, and high yield savings and CDs step into the spotlight. Investors who ignore where households park their deposits risk missing a quiet reshuffle of power between traditional banks and consumer fintech platforms. This article walks through three stocks from our U.S. high yield retail deposit screener that look especially exposed to these crosscurrents. It also explains how the...

3M (MMM) moved back into focus after management settled major PFAS and veterans' earplug lawsuits and lifted its 2026 financial targets following better than expected second quarter results, which signaled higher internal confidence. The recent legal settlements and raised 2026 targets have come alongside mixed trading for 3M, with the share price gaining 2.5% over the past three months but slipping 7.3% over the last 30 days. Total shareholder return over one year sits at 9.8%, and the...

PDD Holdings has recently attracted higher investor attention after earnings estimates for the current quarter and coming fiscal years were revised upward, alongside data showing the stock trading at a discount to peers on several valuation metrics. The combination of improving earnings expectations and a relative valuation discount highlights how investors are reassessing PDD Holdings’ underlying business strength and profit potential rather than just short term trading trends. Next, the...

Recent leadership moves at U.S. Physical Therapy (USPH), including the appointment of Nchacha Etta as Chief Financial Officer and Myra Davis to the Board, have sharpened attention on cost discipline and cash flow quality. The leadership reshuffle at U.S. Physical Therapy is landing at a moment when momentum in the share price has picked up, with a 90-day share price return of 29.87% and a 30-day move of 5.45% off a latest close of US$82.47. That short-term strength contrasts with a weaker...

The market has been flat over the last week but is up 12% over the past year, with earnings expected to grow by 17% per annum in the coming years. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on future growth prospects.

In the last week, the United States market has been flat, yet it has seen a 12% increase over the past year with earnings forecasted to grow by 17% annually. In this environment, growth companies with significant insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests.

The market has stayed flat over the past week but has risen 12% in the last year, with earnings forecasted to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. This article highlights three penny stocks that combine balance sheet strength with potential for outsized gains, providing investors a chance to uncover hidden value in quality...

Stubborn inflation, higher Fed policy rates and pressured household budgets have turned the hunt for resilient income into a far more serious exercise than just chasing yield. Some investors now see high quality dividend payers as potential anchors when fast money trades on every CPI print, and missing the right kind of exposure can feel costly. This article walks through three U.S. dividend stocks from our value-focused screener that appear closely tied to these macro shifts, and explains...